Forest Sees No Significant Impact From Antidepressant "Black Box" Warnings
This article was originally published in The Pink Sheet Daily
Executive Summary
The antidepressant relabeling will only have a "mild" effect on a small part of the business, Forest says. Some of the impact could be offset if competitors scale back on direct-to-consumer advertisements: Pfizer is still running Zoloft TV ads in the days following FDA's decision to require new warnings.
You may also be interested in...
Lexapro Shows Modest Sales Gains With Close Of 2004, Forest Says
Sales of the antidepressant grew 3% sequentially in the quarter ended Dec. 31, but the gains were more than offset by a 50% decline in Celexa due to generic competition. Forest's better-than-expected quarterly earnings performance partially reflects a one-time, $30 mil. sale of the flu therapy Flumadine to the U.S. government.
Lexapro Shows Modest Sales Gains With Close Of 2004, Forest Says
Sales of the antidepressant grew 3% sequentially in the quarter ended Dec. 31, but the gains were more than offset by a 50% decline in Celexa due to generic competition. Forest's better-than-expected quarterly earnings performance partially reflects a one-time, $30 mil. sale of the flu therapy Flumadine to the U.S. government.
Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts
Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.